Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. (AMGN) is a global biotechnology leader pioneering innovative therapies for serious illnesses. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's latest developments, regulatory milestones, and strategic initiatives.
Track critical updates across Amgen's core therapeutic areas including oncology treatments, inflammatory disease therapies, and rare disease solutions. Our curated feed includes earnings reports, clinical trial data, partnership announcements, and manufacturing updates - all sourced directly from official channels.
Key resources include timely coverage of FDA decisions, research breakthroughs in biologics and biosimilars, and analysis of market-moving events. Bookmark this page for structured access to Amgen's evolving pipeline and business strategies without promotional bias.
Amgen's ninth Biosimilar Trends Report, released on October 12, 2022, highlights the growing presence of biosimilars in the U.S. market.
Key findings show that biosimilar share has increased to 75% over the past three years compared to 39% previously. The report estimates that $3.2 billion in savings occurred in Q2 2022 due to biosimilar availability.
As the trend continues, up to seven new biosimilars for HUMIRA are expected by the end of 2023, potentially further reducing costs in healthcare.
Amgen has opened a new 245,000 square foot research and development facility in San Francisco's Oyster Point, marking its ongoing presence in the Bay Area. This facility will focus on therapeutics for cancer, inflammatory diseases, and cardiometabolic disorders. It accommodates 650 staff and features modern, sustainable design aimed at enhancing collaboration. Recognized as a top workplace, Amgen continues to emphasize employee diversity and sustainability. The company's strategic investments in R&D solidify its commitment to innovation and improving health outcomes for patients.
Amgen (NASDAQ:AMGN) will present at Bank of America Merrill Lynch's 2022 Global Healthcare Conference on Sept. 15, 2022, at 4:55 a.m. ET. CFO Peter H. Griffith will lead the presentation, which will be available via webcast for media and investors. Amgen, a leader in biotechnology, focuses on innovative therapeutics for serious illnesses and has been recognized for its workplace culture and sustainability efforts. The webcast will be accessible for replay for at least 90 days on Amgen's website. For more details, visit www.amgen.com.
Amgen (NASDAQ: AMGN) reported promising Phase 1b results from the CodeBreaK 101 study, showcasing a median progression-free survival (PFS) of 5.7 months in patients with KRAS G12C-mutated colorectal cancer. The combination of LUMAKRAS® (sotorasib) and Vectibix® (panitumumab) achieved a 30% confirmed objective response rate in heavily pre-treated patients. Among 40 participants, 92.5% experienced disease control, and tumor shrinkage was observed in 88%. The study emphasizes the need for effective treatments in this challenging patient population.
LUMAKRAS (sotorasib) demonstrates significant progress in treating KRAS G12C-mutated non-small cell lung cancer (NSCLC) according to results from the Phase 3 CodeBreaK 200 trial. At one year, 25% of patients on LUMAKRAS experienced progression-free survival (PFS) compared to 10% for docetaxel. Additionally, the objective response rate (ORR) was **28%** for LUMAKRAS versus **13%** for docetaxel. Fewer treatment-related adverse events were reported with LUMAKRAS, reinforcing its potential as a key treatment option. Amgen plans to submit these findings to global health authorities.
Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 2022 Global Healthcare Conference on Sept. 13, 2022, at 9:10 a.m. ET. CEO Robert A. Bradway will lead the discussion. The event will be webcasted live and accessible to the public. Recorded presentations and updates about Amgen can be found on their website under the Investors section. Amgen, a biotechnology leader since 1980, focuses on innovative therapeutics for serious illnesses, and is part of the Dow Jones Industrial Average and Nasdaq-100 index.
Amgen announced positive results from two Phase 3 studies of Otezla (apremilast) presented at the 31st EADV Congress. The SPROUT study showed significant efficacy in pediatric patients aged 6-17 with moderate to severe plaque psoriasis, achieving a 33.1% response compared to 11.5% for placebo at week 16 (P<0.0001). The DISCREET study demonstrated improvements in adult genital psoriasis, with 38.7% achieving a clear response versus 19.1% for placebo (P=0.0003). Adverse events were consistent with Otezla's established safety profile.
Amgen (NASDAQ:AMGN) will host a webcast for the investment community on Sept. 12, 2022, at 1:30 p.m. ET, during the European Society for Medical Oncology Annual Congress (ESMO). Dr. David M. Reese and Amgen's clinical team will discuss findings from the LUMAKRAS® (sotorasib) CodeBreaK 200 study in non-small cell lung cancer, as well as the Phase 1b expansion of LUMAKRAS with Vectibix® (panitumumab) in colorectal cancer. The webcast will be available to the media, investors, and the public, and archived for 90 days on Amgen's website.
Amgen (NASDAQ:AMGN) will present at Wells Fargo's 2022 Global Healthcare Conference on September 8, 2022, at 9:45 a.m. ET. The presentation will feature David M. Reese, M.D. and Peter H. Griffith, executives of the company. A live webcast will be available to investors and the public, with archival access for 90 days. Amgen aims to improve health outcomes through innovative therapeutics, leveraging advanced human genetics. As a significant player in biotechnology, Amgen is included in the Dow Jones Industrial Average and Nasdaq-100 indices.
Amgen will present at Citi's 2022 Global Healthcare Conference on September 7, 2022, at 8:50 a.m. ET. David M. Reese, M.D., and Peter H. Griffith will represent the company. The presentation will be webcast live for the media, investors, and the public, with an archive available for at least 90 days post-event. Amgen is a biotechnology leader, focusing on innovative therapies and high unmet medical needs. The company is part of the Dow Jones Industrial Average and the Nasdaq-100 index, recognized for its workplace culture and sustainability efforts.
